Administrator for the Centers for Medicare & Medicaid Services Mehmet Oz speaks as U.S. President Donald Trump looks on during an event on drug pricing in the South Court Auditorium on the White House campus on February 5, 2026 in Washington, DC. The president announced the launch of TrumpRx, which the White House said would help lower prescription drug prices.
Getty Images
President Trump signed an executive order earlier this month declaring that imported pharmaceutical products pose a threat to U.S. national security. The order imposed sweeping tariffs on drug companies that refuse to participate in his most-favored-nation pricing initiative.
The new tariffs are imposed under Section 232 of the Trade Expansion Act. This is different from the emergency-powers statute the Supreme Court invalidated earlier this year. MFN pricing requires drugmakers to charge U.S. buyers no more than the lowest price they offer to other comparable wealthy countries.
This is a significant escalation in Trump’s focus on drug prices. After months of voluntary deals with major drugmakers, the order makes it clear the administration will use trade policy as an enforcement mechanism. Companies that play along get a three-year tariff reprieve. Those that don’t face meaningful penalties.
The move underscores the goal of TrumpRx, the direct-to-consumer drug portal the president launched in February 2026, as well as its limits. The administration has now signed 17 MFN deals covering 86% of the branded pharmaceutical market. According to the White House, TrumpRx is “one of the most transformative health care initiatives of all time.”
Yet, the actual story of TrumpRx and drug prices is complicated. Several deal-signers raised list prices on other products at the start of 2026. Also, some of the biggest discounts on TrumpRx apply to drugs already available more cheaply elsewhere. The deals also primarily help cash-paying consumers and Medicaid beneficiaries, leaving out the vast majority of insured Americans.
So, what is TrumpRx, really? As I wrote in an earlier piece when the platform launched, it promises to cut out the middlemen that drive up American drug costs.
Is it the beginning of real drug pricing reform or just another iteration of marginal policies aimed at curbing drug prices? As with most things in health policy, the answer lies somewhere in between: where it lands will depend on what happens next.
The MFN framework took shape in mid-2025, when President Trump sent letters directing major drug manufacturers to align U.S. prices with the lowest prices they charge in comparable OECD nations. The resulting voluntary agreements follow a common structure: manufacturers commit to MFN pricing for cash-paying customers through TrumpRx.gov and for state Medicaid programs. They also agree to launch new drugs at MFN-aligned prices going forward. In exchange, they receive the tariff exemption.
Some of the discounts have been striking. Pfizer’s cuts ranged from 50% to 85% off list price. Ozempic dropped from roughly $1,000 to $350 per month for TrumpRx users. Amgen’s cholesterol drug Repatha fell from $573 to $239.
The administration has also proposed mandatory programs for Medicare: the GLOBE model for Part B drugs and the GUARD model for Part D, both released in December 2025. These would impose mandatory rebates on high-cost single-source drugs benchmarked to international prices. A final rule on GLOBE is expected this summer. For manufacturers watching the regulatory trajectory, signing a voluntary deal may be the better of two options.
TrumpRx’s most significant limitation is its structure. Two groups primarily benefit: people who pay out of pocket without insurance and state Medicaid programs receiving discounted prices for their beneficiaries. Note that Medicaid beneficiaries themselves do not directly benefit because they already have very little cost sharing.
For the roughly 220 million Americans with private health coverage, the MFN agreements change very little. List prices aren’t the prices most insured patients pay. They pay far lower prices after rebates and negotiated discounts. Trump’s deals also don’t require manufacturers to lower or freeze list prices on existing products covered by private insurance.
The drug selection on TrumpRx also raises questions. At launch, 43 drugs were available. As of late April 2026, the number on the site has grown to 86. Yet many of the listed medications already have or will soon have more affordable generic alternatives available through platforms like GoodRx or Mark Cuban’s Cost Plus Drugs.
The pharmaceutical industry’s core objection to MFN pricing is that as the potential upside of innovating is curbed, their investment in new drugs will decline.
The U.S. accounts for a disproportionate share of global pharmaceutical profits. Much of that capital funds R&D for drugs that benefit patients worldwide. Tying U.S. prices to European benchmarks where price controls have been common for decades could reshape those incentives in ways that are difficult to model.
The concern is less about big pharma like Pfizer and Merck, which have diversified pipelines and can absorb pricing pressure. The issue is more for smaller and early-stage biotech companies, such as those that develop rare disease therapies for conditions like Huntington’s disease or cystic fibrosis. They depend heavily on investor expectations of future returns. Such startups may never reach the market if the expected return changes.
By contrast, proponents of drug price reform counter that our current system already underperforms on affordability. Americans pay the world’s highest prices but still face coverage gaps and out-of-pocket costs that drive non-adherence and preventable hospitalizations. The question isn’t whether innovation matters but whether the current pricing architecture is the most efficient way to fund it.
Congressional oversight is intensifying. In early 2026, lawmakers from both parties sent letters requesting copies of the executed MFN agreements, clarification on enforcement mechanisms and analyses of the fiscal impacts on Medicare and Medicaid. Deal terms remain largely confidential: a transparency gap that has drawn bipartisan scrutiny. Without clear data on what manufacturers are actually charging versus the MFN benchmark, independent evaluation of the program’s impact is difficult.
The platform’s early traffic metrics also tell a cautionary story. Website visits to TrumpRx.gov peaked on launch day and have since plummeted. While that pattern is common for government health portals, it raises questions about reach and uptake.
The Inflation Reduction Act’s Medicare Drug Price Negotiation Program adds another layer. Negotiated prices on the first 10 drugs took effect Jan. 1, 2026, generating an estimated $6 billion in annual Medicare savings. CMS is set to negotiate 15 more drugs in 2027 and 15 in 2028. The statutory IRA negotiation and the administration’s MFN initiative run in parallel, sometimes covering different drugs, sometimes overlapping, with interactions regulators are still sorting out.
Ultimately, TrumpRx should be best seen not as a finished reform but as an opening move in a longer negotiation: between the administration and the drug industry, between the executive branch and Congress and between the promise of lower prices and the structural complexity of the American drug market. Voluntary deals have produced real discounts for a defined subset of patients. But for most Americans, prescription drug affordability still depends on insurance coverage, employer benefit design and PBM contracting. To date, TrumpRx addressed none of this.
As the drug pricing discussion moves on, there are many open questions: whether the GLOBE and GUARD models proceed and whether the April 2026 tariff order produces meaningful compliance from holdouts. And most importantly, whether the Trump administration’s drug policies shift focus to the private insurance market. These answers will determine whether 2026 will truly mark a turning point in American drug pricing.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。